CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference

BASEL, Switzerland and CAMBRIDGE, Mass., June 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at the JMP Securities Life Sciences Conference at the St. Regis New York in New York, New York.

Event: JMP Securities Life Sciences ConferencePanel: Gene Editing – Pushing the Frontier for Curing Disease Editing Date: Tuesday, June 20, 2017 Time: 9:00 AM

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 [email protected]

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 [email protected]

You May Also Be Interested In

• Why Visual Asset Repurposing Is Becoming a Competitive Advantage
• $120,000 and One Million Visitors in 48 Hours for Solo Founder's Side Project Outbid.lol
• VOIDTRACE AI Adds Subscription Utility to $VOIDE Through AI Terminal Access